Morningstar26d
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...
rheumatologyadvisor2d
Novel Androgen Receptor Agonist Fast Tracked for Sarcopenia in Cirrhosis
The FDA has granted Fast Track designation to LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.
Business Insider26d
Lipocine granted FDA Fast Track Designation for LPCN 1148
Lipocine (LPCN) announced that the U.S. FDA has granted Fast Track Designation to LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis. LPCN 1148, an oral prodrug of ...
Stockhouse27d
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the POC ...
Monthly Prescribing Reference26d
Novel Androgen Receptor Agonist Fast Tracked for Sarcopenia in Cirrhosis
Sarcopenia is a common complication of decompensated cirrhosis resulting in progressive loss of muscle mass and function. The Food and Drug Administration (FDA) has granted Fast Track designation ...